000129901 001__ 129901
000129901 005__ 20240731103353.0
000129901 0247_ $$2doi$$a10.3390/md21090478
000129901 0248_ $$2sideral$$a136213
000129901 037__ $$aART-2023-136213
000129901 041__ $$aeng
000129901 100__ $$aGraikini, Dimitra$$uUniversidad de Zaragoza
000129901 245__ $$aBioactivity of fucoidan-rich extracts from fucus vesiculosus against rotavirus and foodborne pathogens
000129901 260__ $$c2023
000129901 5060_ $$aAccess copy available to the general public$$fUnrestricted
000129901 5203_ $$aMarine algae are sources of bioactive components with defensive properties of great value against microbial infections. This study investigated the bioactivity of extracts from brown algae Fucus vesiculosus against rotavirus, the worldwide leading cause of acute gastroenteritis in infants and young children. Moreover, one of the extracts was tested against four foodborne bacteria: Campylobacter jejuni, Escherichia coli, Salmonella Typhimurium, and Listeria monocytogenes, and the non-pathogenic: E. coli K12. In vitro tests using MA104 cells revealed that both whole algae extracts and crude fucoidan precipitates neutralized rotavirus in a dose-responsive manner. The maximum neutralization activity was observed when the rotavirus was incubated with 100 μg mL−1 of the hydrochloric acid-obtained crude fucoidan (91.8%), although crude fucoidan extracted using citric acid also demonstrated high values (89.5%) at the same concentration. Furthermore, molecular weight fractionation of extracts decreased their antirotaviral activity and high molecular weight fractions exhibited higher activity compared to those of lower molecular weight. A seaweed extract with high antirotaviral activity was also found to inhibit the growth of C. jejuni, S. Typhimurium, and L. monocytogenes at a concentration of 0.2 mg mL−1. Overall, this study expands the current knowledge regarding the antimicrobial mechanisms of action of extracts from F. vesiculosus.
000129901 536__ $$9info:eu-repo/grantAgreement/ES/DGA/A20-23R$$9info:eu-repo/grantAgreement/EC/H2020/801586/EU/International Doctoral Programme for Talent Attraction to the Campus of International Excellence of the Ebro Valley/IberusTalent$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 801586-IberusTalent$$9info:eu-repo/grantAgreement/ES/MINECO/AGL2017-82987-R
000129901 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000129901 590__ $$a4.9$$b2023
000129901 592__ $$a0.88$$b2023
000129901 591__ $$aPHARMACOLOGY & PHARMACY$$b45 / 354 = 0.127$$c2023$$dQ1$$eT1
000129901 593__ $$aDrug Discovery$$c2023$$dQ1
000129901 591__ $$aCHEMISTRY, MEDICINAL$$b13 / 72 = 0.181$$c2023$$dQ1$$eT1
000129901 593__ $$aPharmacology, Toxicology and Pharmaceutics (miscellaneous)$$c2023$$dQ1
000129901 593__ $$aPharmaceutical Science$$c2023$$dQ1
000129901 594__ $$a9.6$$b2023
000129901 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000129901 700__ $$aSoro, Arturo B.
000129901 700__ $$aSivagnanam, Saravana P.
000129901 700__ $$aTiwari, Brijesh K.
000129901 700__ $$0(orcid)0000-0001-5964-823X$$aSánchez, Lourdes$$uUniversidad de Zaragoza
000129901 7102_ $$12008$$2780$$aUniversidad de Zaragoza$$bDpto. Produc.Animal Cienc.Ali.$$cÁrea Tecnología de Alimentos
000129901 773__ $$g21, 9 (2023), 478 [16 pp.]$$pMar. drugs$$tMarine Drugs$$x1660-3397
000129901 8564_ $$s834441$$uhttps://zaguan.unizar.es/record/129901/files/texto_completo.pdf$$yVersión publicada
000129901 8564_ $$s2648877$$uhttps://zaguan.unizar.es/record/129901/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000129901 909CO $$ooai:zaguan.unizar.es:129901$$particulos$$pdriver
000129901 951__ $$a2024-07-31-09:55:30
000129901 980__ $$aARTICLE